This follows a series of high-profile disappointments in the CD47 space, most notably Gilead’s complete discontinuation of magrolimab after multiple trial holds, including the termination of a Phase 3 study in higher-risk myelodysplastic syndrome (MDS) for futility (Gilead press release, 2023) and the termination of other ongoing MDS trials following cessation of magrolimab development (ClinicalTrials.gov Identifier: NCT05835011; last updated 02 October 2024). Here, CD47 is linked to myelodysplastic syndrome.